ArticleJHLT open2026
Gene expression profiling does not predict long-term risk of malignancy in heart transplant recipients.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart transplant (HT) recipients require immunosuppression for the prevention of graft rejection, but remain at risk for malignancy. AlloMap (CareDx) is a gene expression profiling (GEP) method that can act as a non-invasive alternative to endomyocardial biopsy for surveillance of graft rejection. While higher activation scores are suggestive of rejection, it is unknown if lower scores are correlated with higher risk of malignancy. The aim of this study is to identify the association between AlloMap score and the development of future malignancy. Methods: We conducted a multicenter, retrospective, observational cohort study that included 444 adult HT recipients between 2010 and 2021 who were evaluated with the AlloMap assay. Median AlloMap score was calculated from available scores in the first year after HT. The primary outcome of interest was the development of any Results: No statistically significant association between AlloMap score and the cumulative incidence of Conclusion: AlloMap scores in the first 1 or 2 years after HT were not predictive of long-term malignancy risk in our multicenter study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.